REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could fewer zaps of radiation work just as well for lymphoma?
Disease control Recruiting nowThis study compares a reduced dose of radiation (3 treatments) against the standard 12 treatments for people with indolent non-Hodgkin lymphoma, a slow-growing blood cancer. The goal is to see if the shorter course is safer and still controls the disease. About 112 adults with ce…
Matched conditions: REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether adding an experimental drug (ST-067) to standard CAR T-cell therapy can improve outcomes for people with large B-cell lymphoma that has returned or not responded to prior treatments. About 33 adults will receive the combination to find the safest dose and…
Matched conditions: REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:55 UTC